Dr. Andre Abner Abitbol, MD

Dr. Abitbol practices at Baptist Health Baptist Hospital in Miami, Florida, part of Baptist Health South Florida.

Dr. Abitbol's NPI, 1417944745, was assigned on October 3, 2005. Dr. Abitbol graduated from Emory School of Medicine in 1971. Dr. Abitbol holds Florida license ME40697.

Dr. Abitbol's primary practice is Baptist Health Baptist Hospital, at 8900 N Kendall Dr, Miami, FL 33176 in Miami-Dade County. The practice phone is (786) 596-1960.

Dr. Abitbol's primary practice is Baptist Health Baptist Hospital in Miami, Florida, part of Baptist Health South Florida. The medical group on file is Baptist Health Medical Group Oncology. Dmand AI also links Dr. Abitbol to 1 more breast imaging center, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Abitbol practices, 2 sites in all. Vendor and product names are available with a free account.

Radiation oncology is Dr. Abitbol's primary specialty in the NPI Registry, under taxonomy code 2085R0001X. Dr. Abitbol is board certified in therapeutic radiology by the American Board of Radiology. Dmand AI has Dr. Abitbol's licenses on file in 3 states: Florida, New York and Georgia.

CMS data shows 53 Medicare services from Dr. Abitbol across 3 procedure codes in 2024, for 48 Medicare patients. Medicare paid $2,075 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 48 Medicare patients who saw Dr. Abitbol in 2024. The largest group is 75 to 84, with 19 patients. 75% of them have cancer, and 75% have high cholesterol. 31% are also on Medicaid. Their average risk score is 2.45, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Abitbol's median patient age at 68, with 59% women.

In 2018, Dr. Abitbol wrote 39 Medicare Part D claims. Every claim was for a generic drug. They cover 1 drug, with $1,893 in total drug cost. In 2017, CMS named 78 claims across 3 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 93 out of 100 for Dr. Abitbol for performance year 2024, reported as part of a group. Dr. Abitbol accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 40 papers to Dr. Abitbol, published from 2011 to 2021. The most frequent topics are Radiotherapy Dosage, Carcinoma, Squamous Cell and Brachytherapy. Dr. Abitbol has published most often in Int J Radiat Oncol Biol Phys. Dr. Abitbol's most frequent co-authors are Alan Albert Lewin, MD, Michael Barnet Troner, MD and Sergio M. Gonzalez-Arias, FACS, MD, PhD.

Dmand AI links Dr. Abitbol to 7 clinical trials, 5 of them phase 3 studies. 3 are still active or recruiting. Conditions studied include Carcinoma, Non-Small-Cell Lung, Esophageal Squamous Cell Carcinoma and Gliosarcoma. Radiation Therapy Oncology Group sponsors the most, 4.

CMS Open Payments shows 12 general payments to Dr. Abitbol from 6 drug and device companies from 2016 to 2023. Food and beverage make up the largest share, 100% of the total. Pinnacle Biologics, Inc paid the most, $331.

Dr. Abitbol graduated from Emory School of Medicine in 1971.

Dr. Abitbol is in network with 11 carriers, including Elevance, Excellus BlueCross BlueShield and Aetna. Medicare plans come from the most carriers, 8. Check the plan with the practice before a visit.